Last update 01 Nov 2024
Shanghai Ming Ju Biotechnology Co. Ltd.

Shanghai Ming Ju Biotechnology Co. Ltd.

Private Company|
2017|
Shanghai Shi, China
|
www.jwtherapeutics.com

Overview

Tags

Hemic and Lymphatic Diseases
Immune System Diseases
Neoplasms
Autologous CAR-T

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases3
Hemic and Lymphatic Diseases3
Neoplasms3
Top 5 Drug TypeCount
Autologous CAR-T3
Top 5 TargetCount
CD19(B-lymphocyte antigen CD19)2
CD19 x CD201

Related

3
Drugs associated with Shanghai Ming Ju Biotechnology Co. Ltd.
Relmacabtagene autoleucel
Target
CD19
Mechanism
CD19 modulators
Active Org.
JW Therapeutics (Suzhou) Co., Ltd. [+3]
Originator Org.
JW Therapeutics (Shanghai) Co., Ltd.JW Therapeutics (Shanghai) Co., Ltd.
Active Indication
Mantle cell lymphoma recurrent [+10]
Inactive Indication
B-cell lymphoma refractory [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
CN
First Approval Date01 Sep 2021
Anti-CD19 CAR-T (Shanghai Ming Ju Biotechnology )
Target
CD19
Mechanism
CD19 inhibitors
Active Org.
Shanghai Ming Ju Biotechnology Co. Ltd.Shanghai Ming Ju Biotechnology Co. Ltd.
Originator Org.
Shanghai Ming Ju Biotechnology Co. Ltd.Shanghai Ming Ju Biotechnology Co. Ltd.
Active Indication
Diffuse Large B-Cell Lymphoma
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
JWCAR201
Target
CD19 x CD20
Mechanism
CD19 modulators [+1]
Active Org.
Fudan UniversityFudan University [+1]
Originator Org.
Fudan UniversityFudan University
Active Indication
Large B-cell lymphoma [+2]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
25
Clinical Trials associated with Shanghai Ming Ju Biotechnology Co. Ltd.
NCT06567080 / Not yet recruitingPhase 1IIT
An Open Label, Single Arm Study to Evaluate JWCAR201 Treating B Cell Driven Hematology Malignancy and Autoimmune Diseases
NCT06479356 / RecruitingPhase 2
An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed or Refractory (R/R) LBCL
NCT06414135 / RecruitingPhase 1IIT
A Dose Ranging Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Relmacabtagene Autoleucel (Relma-cel) in Patients With Refractory/Progressive Systemic Sclerosis
100 Clinical Results associated with Shanghai Ming Ju Biotechnology Co. Ltd.
Login to view more data
0 Patents (Medical) associated with Shanghai Ming Ju Biotechnology Co. Ltd.
Login to view more data
100 Deals associated with Shanghai Ming Ju Biotechnology Co. Ltd.
Login to view more data
100 Translational Medicine associated with Shanghai Ming Ju Biotechnology Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
1
2
Phase 2 Clinical
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free